Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study

Journal of Critical Care
Arthur R H van ZantenArmand R J Girbes

Abstract

Optimal dosing of antibiotics is important for efficacy and avoidance of resistance. Fluoroquinolones are frequently used to treat severe infections in critically ill patients. We studied ciprofloxacin pharmacokinetics after administration of 400 mg twice a day (bid) intravenously (IV). Serum concentrations were measured in 32 intensive care unit patients (age, 68.7 +/- 17.4 years; Sepsis-related Organ Failure Assessment (SOFA) scores, 7.3 +/- 3.4). Blood samples were drawn at 7 time points after ciprofloxacin infusion. We evaluated whether areas under the curve (AUCs) exceeded minimal inhibitory concentration (MIC) values of 0.125, 0.25, 0.5, 1.0, and 2.0 mg/L by 125 times and peak concentrations (C(max)) 10 x MIC (C(max)/MIC >10). The AUC/MIC more than 125 was achieved in 100% for MIC 0.125. For MIC values 0.25, 0.5, 1.0, and 2.0, results were 84%, 31%, 3%, and 0%, respectively (P < .01). The C(max)/MIC more than 10 for MIC values of 0.125, 0.25, 0.5, 1.0, and 2.0 was realized in 100%, 97%, 69%, 25%, and 0%, respectively (P < .01). Female sex, SOFA(pulmonary) points, and SOFA(renal) points predicted higher AUC. Cumulative SOFA scores were most predictive of high AUCs. Ciprofloxacin 400 mg bid IV leads to inadequate AUC/MIC an...Continue Reading

References

Jan 1, 1990·Chemotherapy·R RohwedderH Scholl
Mar 1, 1990·Diagnostic Microbiology and Infectious Disease·R W RohwedderH Scholl
Nov 1, 1987·Antimicrobial Agents and Chemotherapy·M Michéa-HamzehpourJ C Pechère
Nov 1, 1988·The Journal of Antimicrobial Chemotherapy·B Ljungberg, I Nilsson-Ehle
May 1, 1987·Antimicrobial Agents and Chemotherapy·T C GasserP O Madsen
Mar 1, 1993·Antimicrobial Agents and Chemotherapy·G L DrusanoH C Standiford
May 1, 1993·Antimicrobial Agents and Chemotherapy·A ForrestJ J Schentag
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J D Turnidge
Dec 5, 1998·Clinical Pharmacokinetics·A P MacGowan, K E Bowker
Jun 29, 2000·Intensive Care Medicine·C Adrie, M R Pinsky
Mar 15, 2003·The American Journal of Medicine·Carmi BartalYaniv Almog
Aug 30, 2003·Journal of Pharmaceutical and Biomedical Analysis·Silvia ImreL Kelemen
Nov 20, 2003·Critical Care : the Official Journal of the Critical Care Forum·Arthur R H van ZantenKees H Polderman
Jan 9, 2004·Infectious Disease Clinics of North America·Paul G AmbroseRobert C Owens
Feb 6, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·P Ruiz-CarreteroV G Casabó
Aug 20, 2004·Journal of Clinical Pharmacology·Brian R OverholserKevin M Sowinski
Jun 16, 2005·International Journal of Antimicrobial Agents·Andries GousHeino Stass
Apr 22, 2006·Therapeutic Drug Monitoring·Ingeborg M van GeijlswijkY Geert van der Meer
Nov 28, 2012·International Journal of Antimicrobial Agents·P Moine, D N Fish

❮ Previous
Next ❯

Citations

Apr 24, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R-J HassingP J van Genderen
Jun 19, 2010·The Journal of Antimicrobial Chemotherapy·Sheryl A Zelenitsky, Robert E Ariano
May 22, 2010·Current Opinion in Anaesthesiology·Julie M VargheseJeffrey Lipman
Dec 17, 2009·Clinical Pharmacokinetics·Andrew A UdyJeffrey Lipman
Mar 10, 2010·Drugs & Aging·Ralf Stahlmann, Hartmut Lode
Dec 3, 2013·Critical Care : the Official Journal of the Critical Care Forum·Clarence ChantJan O Friedrich
Jan 28, 2009·Annales Françaises D'anesthèsie Et De Rèanimation·J TurcJ-Y Martinez
Jul 23, 2014·BMC Pharmacology & Toxicology·Michiel HaesekerAnnelies Verbon
Dec 26, 2012·Advances in Chronic Kidney Disease·William H Fissell
Jun 18, 2011·The Medical Clinics of North America·Maureen K Bolon
Dec 26, 2009·International Journal of Antimicrobial Agents·Judith SendzikRalf Stahlmann
Nov 17, 2009·Infectious Disease Clinics of North America·Maureen K Bolon
Sep 30, 2015·Medicina intensiva·M O CottaJ Lipman
Jun 13, 2015·Clinical Pharmacokinetics·Stéphanie LerouxUNKNOWN TINN (Treat Infections in NeoNates) and GRiP (Global Research in Paediatrics) Consortiums
May 24, 2012·British Journal of Clinical Pharmacology·Michiel HaesekerAnnelies Verbon
May 20, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F B SimeJ A Roberts
Apr 29, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Matthew S ShotwellWilliam H Fissell
Jun 3, 2015·Current Infectious Disease Reports·Stephen Y Liang, Anand Kumar
Mar 8, 2014·Diagnostic Microbiology and Infectious Disease·Stijn BlotJason A Roberts
Jan 19, 2017·Critical Care Medicine·Andrew RhodesR Phillip Dellinger
Jan 20, 2017·Intensive Care Medicine·Andrew RhodesR Phillip Dellinger
Oct 4, 2017·Antimicrobial Agents and Chemotherapy·J M BoonstraJ W C Alffenaar
Oct 30, 2013·Antimicrobial Agents and Chemotherapy·Marjolijn J P van WanrooyJan-Willem C Alffenaar
Aug 27, 2014·Antimicrobial Agents and Chemotherapy·Wei ZhaoUNKNOWN TINN Consortium
Oct 10, 2018·Current Opinion in Infectious Diseases·Aaron J HeffernanJason A Roberts
Feb 1, 2018·Der Anaesthesist·D C RichterC Lichtenstern
Feb 27, 2019·Chinese Medical Journal·Xiang ZhouYun Long
Feb 28, 2019·The Journal of Antimicrobial Chemotherapy·Jason A RobertsFredrik Sjövall
Oct 6, 2017·Der Anaesthesist·D C RichterChristoph Lichtenstern
May 1, 2015·Journal of the Intensive Care Society·Snehal ShahAndreas Fischer
Mar 24, 2018·Drugs·A J HeffernanJ A Roberts
Jan 2, 2020·Pharmaceutics·Aleksandra GostyńskaAnna Jelińska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.